Literature DB >> 9527801

Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV associated with quinolone resistance in Enterococcus faecalis.

E Kanematsu1, T Deguchi, M Yasuda, T Kawamura, Y Nishino, Y Kawada.   

Abstract

The gyrA and parC genes of 31 clinical isolates of Enterococcus faecalis, including fluoroquinolone-resistant isolates, were partially sequenced and analyzed for target alterations. Topoisomerase IV may be a primary target in E. faecalis, but high-level fluoroquinolone resistance was associated with simultaneous alterations in both GyrA and ParC.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9527801      PMCID： PMC105429          DOI： 10.1128/AAC.42.2.433

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  23 in total

1.  ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype.

Authors:  R Muñoz; A G De La Campa
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

2.  Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae.

Authors:  X S Pan; J Ambler; S Mehtar; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

3.  Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance.

Authors:  X S Pan; L M Fisher
Journal:  J Bacteriol       Date:  1996-07       Impact factor: 3.490

4.  Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV in quinolone-resistant clinical isolates of Klebsiella pneumoniae.

Authors:  T Deguchi; A Fukuoka; M Yasuda; M Nakano; S Ozeki; E Kanematsu; Y Nishino; S Ishihara; Y Ban; Y Kawada
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

5.  Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones.

Authors:  X S Pan; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

6.  Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro.

Authors:  J Tankovic; B Perichon; J Duval; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

7.  Development of fluoroquinolone resistance in Enterococcus faecalis and role of mutations in the DNA gyrase gyrA gene.

Authors:  J Tankovic; F Mahjoubi; P Courvalin; J Duval; R Leclerco
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

8.  Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.

Authors:  E Y Ng; M Trucksis; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

9.  Quinolone-resistant Neisseria gonorrhoeae: correlation of alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV with antimicrobial susceptibility profiles.

Authors:  T Deguchi; M Yasuda; M Nakano; S Ozeki; T Ezaki; I Saito; Y Kawada
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

10.  Quinolone-resistant mutants of escherichia coli DNA topoisomerase IV parC gene.

Authors:  Y Kumagai; J I Kato; K Hoshino; T Akasaka; K Sato; H Ikeda
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191
View more
  25 in total

1.  Association of alterations in ParC and GyrA proteins with resistance of clinical isolates of Enterococcus faecium to nine different fluoroquinolones.

Authors:  S Brisse; A C Fluit; U Wagner; P Heisig; D Milatovic; J Verhoef; S Scheuring; K Köhrer; F J Schmitz
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

2.  In vitro development of resistance to six quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus.

Authors:  M Boos; S Mayer; A Fischer; K Köhrer; S Scheuring; P Heisig; J Verhoef; A C Fluit; F J Schmitz
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

3.  Alterations in GyrA and ParC associated with fluoroquinolone resistance in Enterococcus faecium.

Authors:  N A el Amin; S Jalal; B Wretlind
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

4.  Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.

Authors:  E A Coyle; G W Kaatz; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

5.  First characterization of fluoroquinolone resistance in Streptococcus suis.

Authors:  Jose Antonio Escudero; Alvaro San Millan; Ana Catalan; Adela G de la Campa; Estefania Rivero; Gema Lopez; Lucas Dominguez; Miguel Angel Moreno; Bruno Gonzalez-Zorn
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

6.  Epidemiologic relationship between fluoroquinolone-resistant Salmonella enterica Serovar Choleraesuis strains isolated from humans and pigs in Taiwan (1997 to 2002).

Authors:  Chao-Chin Chang; Yi-Hsuan Lin; Chao-Fu Chang; Kuang-Sheng Yeh; Cheng-Hsun Chiu; Chishih Chu; Maw-Sheng Chien; Yuan-Man Hsu; Li-Shu Tsai; Chien-Shun Chiou
Journal:  J Clin Microbiol       Date:  2005-06       Impact factor: 5.948

7.  Mechanisms of and risk factors for fluoroquinolone resistance in clinical Enterococcus faecalis isolates from patients with urinary tract infections.

Authors:  Tomihiko Yasufuku; Katsumi Shigemura; Toshiro Shirakawa; Minori Matsumoto; Yuzo Nakano; Kazushi Tanaka; Soichi Arakawa; Masato Kawabata; Masato Fujisawa
Journal:  J Clin Microbiol       Date:  2011-09-14       Impact factor: 5.948

Review 8.  The Enterococcus: a Model of Adaptability to Its Environment.

Authors:  Mónica García-Solache; Louis B Rice
Journal:  Clin Microbiol Rev       Date:  2019-01-30       Impact factor: 26.132

9.  Alteration in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV in quinolone-resistant clinical isolates of Staphylococcus epidermidis.

Authors:  Z Li; T Deguchi; M Yasuda; T Kawamura; E Kanematsu; Y Nishino; S Ishihara; Y Kawada
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

10.  In vitro activities of garenoxacin (BMS-284756) against Streptococcus pneumoniae, viridans group streptococci, and Enterococcus faecalis compared to those of six other quinolones.

Authors:  Patrick Grohs; Serge Houssaye; Agnès Aubert; Laurent Gutmann; Emmanuelle Varon
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.